Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Sotrovimab for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, June 23, 2022, DRAFT
https://c19sv.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 80% 0.20 [0.01-4.16] death 0/528 2/529 Improvement, RR [CI] Treatment Control Gupta (DB RCT) 89% 0.11 [0.01-2.06] ventilation 0/528 4/529 Gupta (DB RCT) 75% 0.25 [0.11-0.57] progression 7/528 28/529 Gupta (DB RCT) 79% 0.21 [0.09-0.50] death/hosp. 6/528 30/529 Ong 61% 0.39 [0.05-2.90] death 1/19 10/75 Ong 56% 0.44 [0.11-1.73] ICU 2/19 18/75 Ong 59% 0.41 [0.17-0.99] progression 19 (n) 75 (n) Aggarwal (PSM) 89% 0.11 [0.00-0.79] death 0/522 15/1,563 Aggarwal (PSM) 62% 0.38 [0.20-0.67] hosp. 11/522 89/1,563 Zaqout -165% 2.65 [0.60-11.3] progression 4/345 3/583 Aggarwal 38% 0.62 [0.07-2.77] death 1/1,542 7/3,663 Aggarwal 18% 0.82 [0.56-1.18] hosp. 39/1,542 116/3,663 Aggarwal -3% 1.03 [0.80-1.29] progression 93/1,542 224/3,663 Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Self (DB RCT) 11% 0.89 [0.73-1.10] no recov. 22/160 27/178 Self (DB RCT) 7% 0.93 [0.63-1.35] no recov. 160 (n) 178 (n) sotrovimab COVID-19 outcomes c19sv.com Jun 2022 Favors sotrovimab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit